Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.

Jayasekera J, Mandelblatt JS.

J Clin Oncol. 2019 Dec 5:JCO1901525. doi: 10.1200/JCO.19.01525. [Epub ahead of print] No abstract available.

PMID:
31804858
2.

Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype.

Carroll JE, Small BJ, Tometich DB, Zhai W, Zhou X, Luta G, Ahles TA, Saykin AJ, Nudelman KNH, Clapp JD, Jim HS, Jacobsen PB, Hurria A, Graham D, McDonald BC, Denduluri N, Extermann M, Isaacs C, Dilawari AA, Root J, Stern RA, Mandelblatt JS; Thinking and Living With Cancer Study.

Cancer. 2019 Dec 15;125(24):4516-4524. doi: 10.1002/cncr.32489. Epub 2019 Sep 25.

PMID:
31553501
3.

Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis.

Cadham CJ, Jayasekera JC, Advani SM, Fallon SJ, Stephens JL, Braithwaite D, Jeon J, Cao P, Levy DT, Meza R, Taylor KL, Mandelblatt JS; CISNET-SCALE Collaboration.

Lung Cancer. 2019 Sep;135:205-216. doi: 10.1016/j.lungcan.2019.06.024. Epub 2019 Jul 6.

PMID:
31446996
4.

Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.

Mariotto A, Jayasekerea J, Petkov V, Schechter CB, Enewold L, Helzlsouer KJ, Feuer EJ, Mandelblatt JS.

J Natl Cancer Inst. 2019 Apr 24. pii: djz068. doi: 10.1093/jnci/djz068. [Epub ahead of print]

PMID:
31165854
5.

Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.

Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW.

JNCI Cancer Spectr. 2018 Nov;2(4):pky062. doi: 10.1093/jncics/pky062. Epub 2018 Dec 24.

6.

Pretreatment Psychoneurological Symptoms and Their Association With Longitudinal Cognitive Function and Quality of Life in Older Breast Cancer Survivors.

Tometich DB, Small BJ, Carroll JE, Zhai W, Luta G, Zhou X, Kobayashi LC, Ahles T, Saykin AJ, Clapp JD, Jim HSL, Jacobsen PB, Hurria A, Graham D, McDonald BC, Denduluri N, Extermann M, Isaacs C, Dilawari A, Root J, Rini C, Mandelblatt JS; Thinking and Living with Cancer (TLC) Study.

J Pain Symptom Manage. 2019 Mar;57(3):596-606. doi: 10.1016/j.jpainsymman.2018.11.015. Epub 2018 Nov 23.

PMID:
30472317
7.

The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations.

Panattoni L, Lieu TA, Jayasekera J, O'Neill S, Mandelblatt JS, Etzioni R, Phelps CE, Ramsey SD.

Breast Cancer Res Treat. 2019 Jan;173(2):417-427. doi: 10.1007/s10549-018-4988-3. Epub 2018 Oct 10.

PMID:
30306429
8.

Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study.

Mandelblatt JS, Small BJ, Luta G, Hurria A, Jim H, McDonald BC, Graham D, Zhou X, Clapp J, Zhai W, Breen E, Carroll JE, Denduluri N, Dilawari A, Extermann M, Isaacs C, Jacobsen PB, Kobayashi LC, Holohan Nudelman K, Root J, Stern RA, Tometich D, Turner R, VanMeter JW, Saykin AJ, Ahles T.

J Clin Oncol. 2018 Oct 3:JCO1800140. doi: 10.1200/JCO.18.00140. [Epub ahead of print]

PMID:
30281396
9.

Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply.

Plevritis SK, Berry DA, Mandelblatt JS.

JAMA. 2018 Jun 12;319(22):2336. doi: 10.1001/jama.2018.4261. No abstract available.

PMID:
29896623
10.

Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS; CISNET Breast Cancer Working Group members.

Med Decis Making. 2018 Apr;38(1_suppl):3S-8S. doi: 10.1177/0272989X17737507.

11.

Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, Stout NK, van Ballegooijen M.

Med Decis Making. 2018 Apr;38(1_suppl):112S-125S. doi: 10.1177/0272989X17743244.

12.

Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):140S-150S. doi: 10.1177/0272989X17718168.

13.

Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.

Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK.

Med Decis Making. 2018 Apr;38(1_suppl):9S-23S. doi: 10.1177/0272989X17700624.

14.

Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model.

Schechter CB, Near AM, Jayasekera J, Chandler Y, Mandelblatt JS.

Med Decis Making. 2018 Apr;38(1_suppl):66S-77S. doi: 10.1177/0272989X17698685.

15.

The Impact of Using Different Reference Populations on Measurement of Breast Cancer-Related Cognitive Impairment Rates.

Clapp JD, Luta G, Small BJ, Ahles TA, Root JC, Graham D, Hurria A, Jacobsen PB, Jim H, McDonald BC, Stern RA, Saykin AJ, Mandelblatt JS; Thinking and Living with Cancer (TLC) Study.

Arch Clin Neuropsychol. 2018 Dec 1;33(8):956-963. doi: 10.1093/arclin/acx142.

16.

Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age.

Burnside ES, Lee SJ, Bennette C, Near AM, Alagoz O, Huang H, van den Broek JJ, Kim JY, Ergun MA, van Ravesteyn NT, Stout NK, de Koning HJ, Mandelblatt JS.

MDM Policy Pract. 2017 Jul;2. doi: 10.1177/2381468317717982. Epub 2017 Jul 8.

17.

Physician Intervention and Chinese Americans' Colorectal Cancer Screening.

Huei-Yu Wang J, Ma GX, Liang W, Tan Y, Makambi KH, Dong R, Vernon SW, Tu SP, Mandelblatt JS.

Am J Health Behav. 2018 Jan 1;42(1):13-26. doi: 10.5993/AJHB.42.1.2.

18.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

19.

Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

Chandler Y, Schechter CB, Jayasekera J, Near A, O'Neill SC, Isaacs C, Phelps CE, Ray GT, Lieu TA, Ramsey S, Mandelblatt JS.

J Clin Oncol. 2018 Feb 20;36(6):554-562. doi: 10.1200/JCO.2017.74.5034. Epub 2018 Jan 8.

20.

Distinguishing between CISNET model results versus CISNET models.

Berry DA, de Koning HJ, Lee SJ, Mandelblatt JS, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A; CISNET Breast Working Group Principal Investigators.

Cancer. 2018 Mar 1;124(5):1083-1084. doi: 10.1002/cncr.31150. Epub 2017 Dec 26. No abstract available.

21.

Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.

Steffen LE, Du R, Gammon A, Mandelblatt JS, Kohlmann WK, Lee JH, Buys SS, Stroup AM, Campo RA, Flores KG, Vicuña B, Schwartz MD, Kinney AY.

Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1772-1780. doi: 10.1158/1055-9965.EPI-17-0389. Epub 2017 Sep 29.

22.

Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).

Bluethmann SM, Alfano CM, Clapp JD, Luta G, Small BJ, Hurria A, Cohen HJ, Sugarman S, B Muss H, Isaacs C, Mandelblatt JS.

Breast Cancer Res Treat. 2017 Oct;165(3):677-686. doi: 10.1007/s10549-017-4353-y. Epub 2017 Jun 26.

23.

Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance).

Mandelblatt JS, Cai L, Luta G, Kimmick G, Clapp J, Isaacs C, Pitcher B, Barry W, Winer E, Sugarman S, Hudis C, Muss H, Cohen HJ, Hurria A.

Breast Cancer Res Treat. 2017 Jul;164(1):107-117. doi: 10.1007/s10549-017-4222-8. Epub 2017 Mar 31.

24.

Evaluating Frameworks That Provide Value Measures for Health Care Interventions.

Mandelblatt JS, Ramsey SD, Lieu TA, Phelps CE.

Value Health. 2017 Feb;20(2):185-192. doi: 10.1016/j.jval.2016.11.013.

25.

Oncologist and organizational factors associated with variation in breast cancer multigene testing.

Lieu TA, Ray GT, Prausnitz SR, Habel LA, Alexeeff S, Li Y, Ramsey SD, Phelps CE, Chawla N, C O'Neill S, Mandelblatt JS.

Breast Cancer Res Treat. 2017 May;163(1):167-176. doi: 10.1007/s10549-017-4158-z. Epub 2017 Feb 21.

26.

Personality, coping, and social support as predictors of long-term quality-of-life trajectories in older breast cancer survivors: CALGB protocol 369901 (Alliance).

Durá-Ferrandis E, Mandelblatt JS, Clapp J, Luta G, Faul L, Kimmick G, Cohen HJ, Yung RL, Hurria A.

Psychooncology. 2017 Nov;26(11):1914-1921. doi: 10.1002/pon.4404. Epub 2017 Mar 9.

27.

Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.

Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN; Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2016 Nov 15;165(10):700-712. doi: 10.7326/M16-0476. Epub 2016 Aug 23.

28.

Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance).

Mandelblatt JS, Clapp JD, Luta G, Faul LA, Tallarico MD, McClendon TD, Whitley JA, Cai L, Ahles TA, Stern RA, Jacobsen PB, Small BJ, Pitcher BN, Dura-Fernandis E, Muss HB, Hurria A, Cohen HJ, Isaacs C.

Cancer. 2016 Nov 15;122(22):3555-3563. doi: 10.1002/cncr.30208. Epub 2016 Jul 22.

29.

Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up.

Kinney AY, Steffen LE, Brumbach BH, Kohlmann W, Du R, Lee JH, Gammon A, Butler K, Buys SS, Stroup AM, Campo RA, Flores KG, Mandelblatt JS, Schwartz MD.

J Clin Oncol. 2016 Aug 20;34(24):2914-24. doi: 10.1200/JCO.2015.65.9557. Epub 2016 Jun 20.

30.

A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).

Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Buono DL, Nathanson SD, Bovbjerg DH, Mandelblatt JS, Tsai WY, Jacobson JS, Hershman DL.

Breast Cancer Res Treat. 2016 Jul;158(1):127-138. doi: 10.1007/s10549-016-3855-3. Epub 2016 Jun 10.

31.

Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) Study.

Greenlee H, Neugut AI, Falci L, Hillyer GC, Buono D, Mandelblatt JS, Roh JM, Ergas IJ, Kwan ML, Lee M, Tsai WY, Shi Z, Lamerato L, Kushi LH, Hershman DL.

JAMA Oncol. 2016 Sep 1;2(9):1170-6. doi: 10.1001/jamaoncol.2016.0685.

32.

Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL).

Hershman DL, Kushi LH, Hillyer GC, Coromilas E, Buono D, Lamerato L, Bovbjerg DH, Mandelblatt JS, Tsai WY, Zhong X, Jacobson JS, Wright JD, Neugut AI.

Breast Cancer Res Treat. 2016 May;157(1):133-43. doi: 10.1007/s10549-016-3788-x. Epub 2016 Apr 16.

33.

Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas.

Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS, Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS.

J Oncol Pract. 2016 Jan;12(1):59, e1-13. doi: 10.1200/JOP.2015.004838.

34.

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA.

Ann Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536. Epub 2016 Jan 12.

35.

Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis.

van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ.

J Natl Cancer Inst. 2015 May 6;107(7). pii: djv103. doi: 10.1093/jnci/djv103. Print 2015 Jul.

36.

Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program.

van Ravesteyn NT, van Lier L, Schechter CB, Ekwueme DU, Royalty J, Miller JW, Near AM, Cronin KA, Heijnsdijk EA, Mandelblatt JS, de Koning HJ.

Am J Prev Med. 2015 May;48(5):535-42. doi: 10.1016/j.amepre.2014.11.010.

37.

Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.

Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN.

Ann Intern Med. 2015 Feb 3;162(3):157-66. doi: 10.7326/M14-0692.

38.

Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial.

Kinney AY, Butler KM, Schwartz MD, Mandelblatt JS, Boucher KM, Pappas LM, Gammon A, Kohlmann W, Edwards SL, Stroup AM, Buys SS, Flores KG, Campo RA.

J Natl Cancer Inst. 2014 Nov 5;106(12). pii: dju328. doi: 10.1093/jnci/dju328. Print 2014 Dec.

39.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju289. doi: 10.1093/jnci/dju289. Print 2014 Nov.

40.

Chemobrain: is it time to initiate guidelines for assessment and management?

Patel SK, Hurria A, Mandelblatt JS.

Oncology (Williston Park). 2014 Sep;28(9):809-10. No abstract available.

41.

Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data.

Mandelblatt JS, Huang K, Makgoeng SB, Luta G, Song JX, Tallarico M, Roh JM, Munneke JR, Houlston CA, McGuckin ME, Cai L, Clarke Hillyer G, Hershman DL, Neugut AI, Isaacs C, Kushi L.

J Oncol Pract. 2015 Jan;11(1):e1-8. doi: 10.1200/JOP.2013.001288. Epub 2014 Aug 26.

42.

Promoting Chinese-speaking primary care physicians' communication with immigrant patients about colorectal cancer screening: a cluster randomized trial design.

Wang JH, Liang W, Ma GX, Gehan E, Wang HE, Ji CS, Tu SP, Vernon SW, Mandelblatt JS.

J Health Care Poor Underserved. 2014 Aug;25(3):1079-100. doi: 10.1353/hpu.2014.0114.

43.

Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors.

Mandelblatt JS, Jacobsen PB, Ahles T.

J Clin Oncol. 2014 Aug 20;32(24):2617-26. doi: 10.1200/JCO.2014.55.1259. Epub 2014 Jul 28. Review.

44.

Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.

Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS.

Ann Intern Med. 2014 Jul 15;161(2):104-12. doi: 10.7326/M13-2867.

45.

An Examination of Factors Associated with Healthcare Discrimination in Latina Immigrants: The Role of Healthcare Relationships and Language.

Sheppard VB, Williams KP, Wang J, Shavers V, Mandelblatt JS.

J Natl Med Assoc. Summer 2014;106(1):15-22. doi: 10.1016/S0027-9684(15)30066-3.

46.

Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.

Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher BN, Hudis C, Winer EP, Cohen HJ, Muss HB, Hurria A, Mandelblatt JS.

J Clin Oncol. 2014 Aug 1;32(22):2318-27. doi: 10.1200/JCO.2013.51.7367. Epub 2014 Jun 16.

47.

Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901.

Faul LA, Luta G, Sheppard V, Isaacs C, Cohen HJ, Muss HB, Yung R, Clapp JD, Winer E, Hudis C, Tallarico M, Wang J, Barry WT, Mandelblatt JS.

J Cancer Surviv. 2014 Dec;8(4):627-37. doi: 10.1007/s11764-014-0371-5. Epub 2014 Jun 11.

48.

Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer.

Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Ambrosone CB, Bovbjerg DH, Mandelblatt JS, Hershman DL.

Breast Cancer. 2014 Nov;21(6):780-5. doi: 10.1007/s12282-014-0543-1. Epub 2014 Jun 6.

49.

Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.

Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS.

J Natl Cancer Inst. 2014 May 28;106(6):dju092. doi: 10.1093/jnci/dju092. Print 2014 Jun.

50.

Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?

Mandelblatt JS, Stern RA, Luta G, McGuckin M, Clapp JD, Hurria A, Jacobsen PB, Faul LA, Isaacs C, Denduluri N, Gavett B, Traina TA, Johnson P, Silliman RA, Turner RS, Howard D, Van Meter JW, Saykin A, Ahles T.

J Clin Oncol. 2014 Jun 20;32(18):1909-18. doi: 10.1200/JCO.2013.54.2050. Epub 2014 May 19.

Supplemental Content

Loading ...
Support Center